Multi-Sample Array Chip for Low-Level 5-hmC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for detecting epigenetic DNA modifications, such as 5-hydroxymethylcytosine (5-hmC), are limited by low sensitivity, require large DNA amounts, and lack high-throughput capabilities, making them unsuitable for clinical applications, especially in samples with low modification levels.
Innovation Solution
A method utilizing a multi-array slide chip with positively charged addressable regions surrounded by hydrophobic areas to electrostatically attach DNA, allowing for sensitive detection and quantification of epigenetic modifications using fluorescent labeling and imaging, even with nanogram quantities of DNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If antibody-based assays (ELISA, dot-blot, IHC) are used for detecting 5-hmC, then the assay simplicity is improved, but the sensitivity and resolution deteriorate, failing to detect low 5-hmC levels in cancerous and healthy tissues
Solution Approach 1:
The patent introduces T4 beta-glucosyltransferase as an intermediary enzyme that specifically recognizes and modifies 5-hmC by adding a glucose moiety. This enzymatic intermediary step enables highly specific and sensitive detection of 5-hmC, overcoming the low sensitivity of direct antibody-based methods while maintaining operational simplicity through a standardized assay protocol
Solution Approach 2:
The patent changes the detection parameter from direct antibody binding to enzymatic modification followed by fluorescent labeling. By transforming 5-hmC into a glucosylated form and then attaching fluorescent tags, the detection sensitivity and resolution are dramatically improved, enabling detection of low 5-hmC levels in clinical samples
2Measurement precision
If HPLC-MS is used for global quantification of 5-hmC, then the accuracy is improved, but the equipment cost, time requirement, and DNA amount needed increase
Solution Approach 1:
The patent replaces the complex mechanical HPLC-MS system with a biochemical assay system using T4 beta-glucosyltransferase enzyme and fluorescent labeling. This substitution maintains high accuracy in 5-hmC quantification while dramatically reducing equipment cost, simplifying the workflow, and enabling detection with nanogram quantities of DNA
Solution Approach 2:
The patent uses fluorescent labeling to create optical signal changes for detecting 5-hmC. By attaching fluorescent tags to glucosylated 5-hmC, the method achieves high accuracy quantification through fluorescence intensity measurement, eliminating the need for expensive mass spectrometry equipment while maintaining precision
3Quantity of substance
If conventional assays are used for detecting epigenetic modifications, then the DNA amount required is large, but the sensitivity for low modification levels deteriorates
Solution Approach 1:
The patent segments the detection process into distinct steps: enzymatic modification of 5-hmC by T4 beta-glucosyltransferase, followed by fluorescent labeling, and finally detection. This segmentation allows for signal amplification and enables sensitive detection of low 5-hmC levels in limited DNA samples, achieving both low DNA requirement and high sensitivity
Solution Approach 2:
The patent performs preliminary enzymatic modification of 5-hmC with T4 beta-glucosyltransferase before detection. This preliminary action creates a unique glucosylated form of 5-hmC that can be specifically labeled and detected with high sensitivity, enabling accurate measurement even in nanogram quantities of DNA
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-throughput, cost-effective, and sensitive detection of epigenetic modifications like 5-hmC in clinical samples, including those with low modification levels, facilitating early cancer diagnosis and treatment monitoring.
Implementation Method 1
contacting an aqueous solution comprising the DNA molecule with at least one addressable region on a surface of a substrate, wherein the addressable region comprises a positively charged substance capable of attaching the DNA molecule to the surface
Implementation Method 2
the addressable region is surrounded by a hydrophobic region of the surface
Implementation Method 3
determining an amount of the at least one first labeling agent in the addressable region, thereby detecting the epigenetic DNA modification
Data Source
AI summary
A method of detecting an epigenetic DNA modification is described herein, the method comprising: attaching to DNA a labeling agent selective for the DNA modification; contacting an aqueous solution comprising the DNA with at least one addressable region on a surface of a substrate, wherein the addressable region comprises a positively charged substance capable of attaching the DNA to the surface, and the addressable region is surrounded by a hydrophobic region; and determining an amount of labeling agent in the addressable region. Further described herein is a kit comprising a substrate comprising discrete hydrophilic regions separated by a hydrophobic region, and a labeling agent selective for an epigenetic DNA modification; as well as an article of manufacture comprising a substrate comprising a discrete regions separated by a hydrophobic region, a positively charged substance and DNA attached thereto, the DNA comprising such a labeling agent.